Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial
Titel:
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial
Auteur:
Romera, Alvaro Peredpaya, Sergiy Shparyk, Yaroslav Bondarenko, Igor Mendonça Bariani, Giovanni Abdalla, Kathia Cristina Roca, Enrique Franke, Fábio Melo Cruz, Felipe Ramesh, Anita Ostwal, Vikas Shah, Pradeep Rahuman, Sajeed Abdul Paravisini, Alexandra Huerga, Camino Del Campo García, Ana Millán, Susana